Study of Inotuzumab Ozogamicin in Children and Young Adults w/CD22+ B-Acute Lymphoblastic Leukemia - Clinical Trial

Email to Participate

lars.wagner@duke.edu

What is the Purpose of this Study?

Si elige unirse a este estudio, podrá:

Get 2-6 cycles of Inotuzumab Ozagamicin, lasting 1 month per cycle
Get Methotrexate on day one during cycle 1 and on day 28 of cycles 2, 4 and 6
Get about 3-5 mL of blood collected prior to treatment and at three time points during cycle 1 and 4 time points during cycle 2

What is the Condition Being Studied?

Niños y adultos jóvenes con leucemia linfoblástica aguda CD22+ B recidivante o refractaria (B-ALL)

Who Can Participate in the Study?

Children and young adults who:

Are 1-22 years of age
Currently have or previously been diagnosed with B-Acute Lymphoblastic Leukemia (B-ALL)
Have recovered from any previous systemic therapy

For more information, contact the study team at diana.sedito@duke.edu.

Grupo etario

Adults, Children

What is Involved?

Estamos llevando a cabo este estudio para determinar qué efectos (buenos y/o malos) tiene el fármaco del estudio Inotuzumab Ozogamicin en niños y jóvenes adultos con LLA-B recidivante o refractaria.

Study Details

Full Title

AALL1621 Un estudio de fase 2 de inotuzumab ozogamicina (NSC# 772518, IND# 133494) en niños y adultos jóvenes con leucemia linfoblástica aguda CD22+ recidivante o refractaria)

Principal Investigator